Arbutus Biopharma (ABUS) Intangibles (2015 - 2019)
Arbutus Biopharma (ABUS) posted Intangibles of $43.8 million for Q2 2019, little changed sequentially from $43.8 million in Q1 2019, and down 25.25% YoY from $58.6 million in Q2 2018.
Arbutus Biopharma (ABUS) Intangibles (2015 - 2019) Analysis & Trends
Arbutus Biopharma has reported Intangibles for 5 years, with the latest figure at $43.8 million in Q2 2019.
- Quarterly Intangibles fell 25.25% year-over-year to $43.8 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $43.8 million (down 25.25% YoY) and the FY2018 annual result came in at $43.8 million, down 25.25% from the prior year.
- Intangibles was little changed at $43.8 million in Q2 2019 per ABUS's latest filing, from $43.8 million in the prior quarter.
- Over five years, Intangibles peaked at $390.0 million in Q2 2015 and troughed at $43.8 million in Q3 2018.
- A 5-year average of $165.6 million and a median of $99.4 million in 2016 frame the typical range for Intangibles.
- The widest YoY moves for Intangibles: up 9.5% in 2016, down 71.8% in 2016.
- Over 5 years, Intangibles stood at $352.6 million in 2015, then tumbled by 71.8% to $99.4 million in 2016, then tumbled by 41.03% to $58.6 million in 2017, then retreated by 25.25% to $43.8 million in 2018, then changed by 0.0% to $43.8 million in 2019.
- According to Business Quant data, Intangibles over the past three periods registered $43.8 million, $43.8 million, and $43.8 million for Q2 2019, Q1 2019, and Q4 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 43.84 Mn |
| Mar 31, 2019 | 43.84 Mn |
| Dec 31, 2018 | 43.84 Mn |
| Sep 30, 2018 | 43.84 Mn |
| Jun 30, 2018 | 58.65 Mn |
| Mar 31, 2018 | 58.65 Mn |
| Dec 31, 2017 | 58.65 Mn |
| Sep 30, 2017 | 99.45 Mn |
| Jun 30, 2017 | 99.45 Mn |
| Mar 31, 2017 | 99.45 Mn |
| Dec 31, 2016 | 99.45 Mn |
| Sep 30, 2016 | 196.32 Mn |
| Jun 30, 2016 | 196.32 Mn |
| Mar 31, 2016 | 352.64 Mn |
| Dec 31, 2015 | 352.64 Mn |
| Sep 30, 2015 | 353.60 Mn |
| Jun 30, 2015 | 390.02 Mn |
| Mar 31, 2015 | 389.65 Mn |